Department of Anatomic Pathology, Cleveland Clinic, Cleveland, OH, USA.
Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA.
Virchows Arch. 2022 Jul;481(1):63-72. doi: 10.1007/s00428-022-03332-5. Epub 2022 May 6.
Lymph nodes with acellular mucin harvested from treated colorectal cancers (CRC) are staged as pN0. However, there is variability among pathologists while reporting the pN stage when acellular mucin is found within nodes of untreated CRCs. While the UICC guidelines suggest staging them as pN1, the AJCC and CAP do not offer any recommendations. In order to characterize their clinicopathologic features and outcome, we compared 16 untreated CRCs (study group; mean age: 68 years) harboring nodes with acellular mucin with 34 pN0 and 25 pN1 untreated CRC controls. All tumors were unifocal; 12 (75%) were right-sided lesions. Most cases (75%) showed one node with acellular mucin (range: 1-3). MMR-deficient tumors were significantly more common in the study group (83%) compared to pN0 (33%; p = 0.006) and pN1 controls (8%; p < 0.001). The overall survival of study group patients was closer to pN0 compared to pN1 controls; however, this difference was not statistically significant. In conclusion, untreated CRC that harbor acellular mucin within lymph nodes commonly present as right-sided, MMR-deficient tumors in older women that show a non-mucinous phenotype. While the limited number of cases precludes us from making any formal recommendations about staging, we suggest that the finding of acellular mucin in a node should prompt evaluation of deeper levels (with or without cytokeratin immunohistochemistry) and submission of all pericolonic fat for additional lymph node harvest. Whether acellular mucin in nodes of untreated CRCs is related to the indolent biology of the disease, a robust local immune response or MMR deficiency requires further investigation.
从治疗后的结直肠癌 (CRC) 中采集的无细胞黏蛋白的淋巴结被分期为 pN0。然而,当未治疗的 CRC 淋巴结中发现无细胞黏蛋白时,病理学家在报告 pN 分期方面存在差异。虽然 UICC 指南建议将其分期为 pN1,但 AJCC 和 CAP 并未提出任何建议。为了描述其临床病理特征和结局,我们比较了 16 例未治疗的 CRC(研究组;平均年龄:68 岁),这些 CRC 中含有无细胞黏蛋白的淋巴结,以及 34 例 pN0 和 25 例 pN1 未治疗的 CRC 对照组。所有肿瘤均为单病灶;12 例(75%)为右侧病变。大多数病例(75%)显示一个淋巴结有无细胞黏蛋白(范围:1-3 个)。与 pN0(33%;p=0.006)和 pN1 对照组(8%;p<0.001)相比,研究组中 MMR 缺陷型肿瘤明显更为常见(83%)。研究组患者的总体生存率与 pN0 相比更接近 pN1 对照组;然而,这种差异无统计学意义。总之,无细胞黏蛋白在淋巴结内的未治疗 CRC 通常表现为右侧、MMR 缺陷型肿瘤,发生于老年女性,表现为非黏液表型。由于病例数量有限,我们无法对分期提出任何正式建议,但我们建议在淋巴结中发现无细胞黏蛋白时,应提示评估更深层次的水平(是否进行细胞角蛋白免疫组化),并提交所有结旁脂肪以进行额外的淋巴结采集。未治疗的 CRC 淋巴结中无细胞黏蛋白是否与疾病的惰性生物学、强大的局部免疫反应或 MMR 缺陷有关,还需要进一步研究。